Comparative Pharmacology
Head-to-head clinical analysis: PALLADONE versus TALWIN 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PALLADONE versus TALWIN 50.
PALLADONE vs TALWIN 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
Pentazocine is a mixed agonist-antagonist opioid analgesic with activity at kappa opioid receptors (agonist) and mu opioid receptors (partial agonist/antagonist). It also exhibits weak antagonistic activity at mu receptors, which reduces abuse liability but may precipitate withdrawal in opioid-dependent patients.
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
50 mg orally every 3-4 hours as needed; maximum 600 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Terminal elimination half-life is 2-3 hours. In patients with hepatic impairment, half-life may extend to 5-8 hours; in renal impairment, minimal change, but active metabolite accumulation may occur.
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Primarily renal (60-70% as unchanged drug and conjugates), with 20-30% biliary/fecal elimination. Approximately 5-10% excreted in feces via bile.
Category C
Category C
Opioid Analgesic
Opioid Analgesic